Megna Michael R

CHIEF ACCOUNTING OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Apr 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
3 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 1, 2026Tax withholding(F)3K$48.13$154K32K
Apr 1, 2026Option exercise(M)8K35K
Jan 15, 2026Grant(A)372$24.16$9K27K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 1, 2026Grant(A)7K$07K
Apr 1, 2026Option exercise(M)3K$03K
Apr 1, 2026Option exercise(M)2K$05K
Apr 1, 2026Option exercise(M)3K$08K
Apr 1, 2026Grant(A)15K$015K
Apr 1, 2026Grant(A)4K$04K

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001464583-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.